These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26192359)

  • 1. Effect of jet injection on infectivity of measles, mumps, and rubella vaccine in a bench model.
    Coughlin MM; Collins M; Saxon G; Jarrahian C; Zehrung D; Cappello C; Dhere R; Royals M; Papania M; Rota PA
    Vaccine; 2015 Aug; 33(36):4540-7. PubMed ID: 26192359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in healthy Brazilian infants: a randomized non-inferiority study.
    de Menezes Martins R; Curran B; Maia Mde L; Ribeiro Md; Camacho LA; da Silva Freire M; Yamamura AM; Siqueira MM; Lemos MC; de Albuquerque EM; von Doellinger Vdos R; Homma A; Saganic L; Jarrahian C; Royals M; Zehrung D
    Contemp Clin Trials; 2015 Mar; 41():1-8. PubMed ID: 25476584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: A randomized, parallel group, non-inferiority trial.
    Bavdekar A; Oswal J; Ramanan PV; Aundhkar C; Venugopal P; Kapse D; Miller T; McGray S; Zehrung D; Kulkarni PS;
    Vaccine; 2018 Feb; 36(9):1220-1226. PubMed ID: 29395526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potency estimation of measles, mumps and rubella trivalent vaccines with quantitative PCR infectivity assay.
    Schalk JA; de Vries CG; Jongen PM
    Biologicals; 2005 Jun; 33(2):71-9. PubMed ID: 15939284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification of measles, mumps and rubella viruses using real-time quantitative TaqMan-based RT-PCR assay.
    Ammour Y; Faizuloev E; Borisova T; Nikonova A; Dmitriev G; Lobodanov S; Zverev V
    J Virol Methods; 2013 Jan; 187(1):57-64. PubMed ID: 23018058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical immunogenicity of measles, mumps and rubella vaccine delivered by the Injex jet injector: comparison with standard syringe injection.
    Sarno MJ; Blase E; Galindo N; Ramirez R; Schirmer CL; Trujillo-Juarez DF
    Pediatr Infect Dis J; 2000 Sep; 19(9):839-42. PubMed ID: 11001106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of measles, mumps and rubella viruses by immuno-colorimetric assay and its application in focus reduction neutralization tests.
    Vaidya SR; Kumbhar NS; Bhide VS
    Microbiol Immunol; 2014 Dec; 58(12):666-74. PubMed ID: 25244651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement in potency assay of measles-mumps-rubella trivalent vaccine: interference between components and measures for its elimination.
    Umino Y; Saito S; Fukuda A; Hishiyama M; Sugiura A
    J Virol Methods; 1990 Feb; 27(2):159-68. PubMed ID: 1690744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella.
    Nascimento Silva JR; Camacho LA; Siqueira MM; Freire Mde S; Castro YP; Maia Mde L; Yamamura AM; Martins RM; Leal Mde L;
    Vaccine; 2011 Aug; 29(37):6327-34. PubMed ID: 21640779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of serum antibodies against measles, mumps and rubella after primary measles, mumps and rubella (MMR) vaccination in children.
    Rafiei Tabatabaei S; Esteghamati AR; Shiva F; Fallah F; Radmanesh R; Abdinia B; Shamshiri AR; Khairkhah M; Shekari Ebrahimabad H; Karimi A
    Arch Iran Med; 2013 Jan; 16(1):38-41. PubMed ID: 23273235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
    Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P
    Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K; Nicoara C; Germann D; Matter L
    Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do HIV-positive adult immigrants need to be screened for measles-mumps-rubella and varicella zoster virus immunization?
    Llenas-García J; Rubio R; Hernando A; Arrazola P; Pulido F
    AIDS Care; 2013 Aug; 25(8):980-9. PubMed ID: 23244745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimation of the number of infectious measles viruses in live virus vaccines using quantitative real-time PCR.
    Schalk JA; van den Elzen C; Ovelgönne H; Baas C; Jongen PM
    J Virol Methods; 2004 May; 117(2):179-87. PubMed ID: 15041215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlates of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children.
    Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA
    Clin Immunol; 2005 May; 115(2):154-61. PubMed ID: 15885638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study and evaluation of further attenuated, live measles vaccines alone and in combination with mumps and rubella vaccines.
    Wegmann A; Glück R; Just M; Mischler R; Paroz P; Germanier R
    Dev Biol Stand; 1986; 65():69-74. PubMed ID: 3556778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
    Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM;
    Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Waning antibody levels and avidity: implications for MMR vaccine-induced protection.
    Kontio M; Jokinen S; Paunio M; Peltola H; Davidkin I
    J Infect Dis; 2012 Nov; 206(10):1542-8. PubMed ID: 22966129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes.
    Saffar MJ; Fathpour GR; Parsaei MR; Ajami A; Khalilian AR; Shojaei J; Saffar H
    J Trop Pediatr; 2011 Oct; 57(5):347-51. PubMed ID: 21078605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.